Exercise and Neuropathic Pain: A General Overview of Preclinical and Clinical Research
Authors:
Open Access
- 22 March 2021
- journal article
- review article
- Published by Springer Nature in Sports Medicine - Open
- Vol. 7 (1) , 1-16
Abstract
Neuropathic pain is a disease of the somatosensory system that is characterized by tingling, burning, and/or shooting pain. Medication is often the primary treatment, but it can be costly, thus there is an interest in understanding alternative low-cost treatments such as exercise. The following review includes an overview of the preclinical and clinical literature examining the influence of exercise on neuropathic pain. Preclinical studies support the hypothesis that exercise reduces hyperalgesia and allodynia in animal models of neuropathic pain. In human research, observational studies suggest that those who are more physically active have lower risk of developing neuropathic pain compared to those who are less active. Exercise studies suggest aerobic exercise training (e.g., 16 weeks); a combination of aerobic and resistance exercise training (e.g., 10–12 weeks); or high-intensity interval training (e.g., 15 weeks) reduces aspects of neuropathic pain such as worst pain over the past month, pain over the past 24 h, pain scores, or pain interference. However, not all measures of pain improve following exercise training (e.g., current pain, heat pain threshold). Potential mechanisms and future directions are also discussed to aid in the goal of understanding the role of exercise in the management of neuropathic pain. Future research using standardized methods to further understanding of the dose of exercise needed to manage neuropathic pain is warranted.Keywords
This publication has 107 references indexed in Scilit:
- The Maintenance of Cisplatin- and Paclitaxel-Induced Mechanical and Cold Allodynia is Suppressed by Cannabinoid CB2 Receptor Activation and Independent of CXCR4 Signaling in Models of Chemotherapy-Induced Peripheral NeuropathyMolecular Pain, 2012
- Chronic Pain, Perceived Stress, and Cellular Aging: An Exploratory StudyMolecular Pain, 2012
- Central sensitization: Implications for the diagnosis and treatment of painPain, 2011
- The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effectsNeuropharmacology, 2011
- The Blockade of the Transient Receptor Potential Vanilloid Type 1 and Fatty Acid Amide Hydrolase Decreases Symptoms and Central Sequelae in the Medial Prefrontal Cortex of Neuropathic RatsMolecular Pain, 2011
- The Temporal-Spatial Encoding of Acupuncture Effects in the BrainMolecular Pain, 2011
- Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid systemNature Neuroscience, 2010
- EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revisionEuropean Journal of Neurology, 2010
- Neuropathic Pain: A Maladaptive Response of the Nervous System to DamageAnnual Review of Neuroscience, 2009
- Modulation of the anti‐nociceptive effects of 2‐arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain modelBritish Journal of Pharmacology, 2008